Faknostics, LLC
Phoenix, AZ · Biotech · Private
First-in-class FAK scaffolding domain inhibitors for idiopathic pulmonary fibrosis
- Grants
- $4.9M
- 9 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20192020202120222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Discovery of Novel Peptidic Inhibitors of the Non-Catalytic Function of Focal Adhesion Kinase (FAK) | $289,594 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of Non-Catalytic Peptide Inhibitors of Focal Adhesion Kinase (FAK) for Use in Melanoma | $674,537 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of Non-Catalytic Peptide Inhibitors of Focal Adhesion Kinase (FAK) for Use in Melanoma | $670,756 | |
| Federal grant | Department of Health and Human Services · Phase I · Non-catalytic FAK inhibitors as novel therapeutics for lung fibrosis | $299,905 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of Non-Catalytic Peptide Inhibitors of Focal Adhesion Kinase (FAK) for Use in Melanoma | $654,706 | |
| Federal grant | Department of Health and Human Services · Phase II · Non-catalytic FAK inhibitors as novel therapeutics for lung fibrosis | $673,796 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel Paxillin-FAK Inhibitors for the Treatment of Liver Fibrosis | $325,976 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel Paxillin-FAK Inhibitors for the Treatment of Liver Fibrosis | $663,777 | |
| Federal grant | Department of Health and Human Services · Phase II · Non-catalytic FAK inhibitors as novel therapeutics for lung fibrosis | $663,310 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1788 | AGILE THERAPEUTICS INC | — | $81M |
| 1789 | Neurogastrx, Inc. | — | $80M |
| 1790 | Azafaros | — | — |
| 1791 | Faknostics, LLC | — | — |
| 1792 | Green Growth Brands Inc. | — | $17M |
| 1793 | PMed Holdings, LLC | — | $1.6M |
| 1794 | Mekanistic Therapeutics, LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.